Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    72
    ...
ATC Name B/G Ingredients Dosage Form Price
N06AX26 BRINTELLIX B Vortioxetine - 10mg 10mg Tablet, film coated 4,345,987 L.L
A03FA03 MOTIDOL ODT G Domperidone - 10mg 10mg Tablet, orodispersible 259,810 L.L
H02AB07 PREDICOR G Prednisone - 10mg 10mg Tablet, scored 386,515 L.L
N06AX26 LYTIOX G Vortioxetine - 10mg 10mg Tablet, film coated 2,064,142 L.L
H02AB07 PREDNISONE G Prednisone - 10mg 10mg Tablet, scored 386,515 L.L
C02KX04 OPSUMIT B Macitentan - 10mg 10mg Tablet, film coated L.L
C08CA01 AMLINE G Amlodipine - 10mg 10mg Tablet 662,962 L.L
N06BA04 RITALIN B Methylphenidate HCl - 10mg 10mg Tablet 376,276 L.L
C08CA01 AMLOCARD 10 G Amlodipine (besylate) - 10mg 10mg Tablet 870,298 L.L
H02AB09 HYDROCORTISONE ROUSSEL B Hydrocortisone - 10mg 10mg Tablet, scored 260,705 L.L
C08CA01 AMLODAR 10 G Amlodipine (besylate) - 10mg 10mg Capsule 671,921 L.L
C08CA01 AMLODIPINE ARROW G Amlodipine (besylate) - 10mg 10mg Capsule 462,282 L.L
C08CA01 AMLODIPINE BIOGARAN G Amlodipine (besylate) - 10mg 10mg Capsule 462,282 L.L
C08CA01 AMLOKEY G Amlodipine (besylate) - 10mg 10mg Tablet 397,777 L.L
C08CA01 AMLORINE 10 G Amlodipine (besylate) - 10mg 10mg Tablet 959,504 L.L
C08CA01 NIPIDOL G Amlodipine - 10mg 10mg Tablet 377,620 L.L
C08CA01 TORANS G Amlodipine (besylate) - 10mg 10mg Tablet 716,716 L.L
H03BB02 THYROZOL B Methimazole (Thiamazole) - 10mg 10mg Tablet, film coated 326,554 L.L
N06BA09 APO-ATOMOXETINE G Atomoxetine (HCl) - 10mg 10mg Capsule 2,981,987 L.L
N05AH03 ZYPREXA VELOTAB B Olanzapine - 10mg 10mg Tablet, dispersible 5,214,109 L.L
L04AX04 REVLIMID B Lenalidomide - 10mg 10mg Capsule L.L
N05AH03 ZYPREXA VELOTAB B Olanzapine - 10mg 10mg Tablet, dispersible 5,214,109 L.L
C08CA13 LERCADIP B Lercanidipine HCl - 10mg 10mg Tablet, film-scored 1,021,320 L.L
N05AH03 APO-OLANZAPINE ODT G Olanzapine - 10mg 10mg Tablet, orally disintegrating 2,422,948 L.L
N05AH03 OLANZAX 10 G Olanzapine - 10mg 10mg Tablet, mouth dissolving 2,329,327 L.L
N05AH03 PRANZA G Olanzapine - 10mg 10mg Tablet, orodispersible 3,553,120 L.L
L01EX08 LENVIMA B Lenvatinib - 10mg 10mg Capsule, hard L.L
N05AH03 VAINCOR G Olanzapine - 10mg 10mg Tablet, coated, scored 1,209,458 L.L
N05AH03 ZOLAPINE G Olanzapine - 10mg 10mg Tablet, orodispersible 2,106,249 L.L
N05AH03 ZYRWAN OD G Olanzapine - 10mg 10mg Tablet, orodispersible 2,564,819 L.L
    ...
    72
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025